Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatment
about
Clinical biomarkers and pathogenic-related cytokines in rheumatoid arthritisUpdated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001)Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002).Autoantibodies against interleukin 1alpha in rheumatoid arthritis: association with long term radiographic outcome.Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007TNFalpha blockade in human diseases: mechanisms and future directions.Effect of TNF antagonists on the productivity of daily work of patients with rheumatoid arthritis.Exploring interaction of TNF and orthopoxviral CrmB protein by surface plasmon resonance and free energy calculation.Effects of dialkoxylphenyl compounds with oxime group on macrophage function and the proliferation of lymphocytes.Angiogenesis and VEGF-expressing cells are identified predominantly in the fascia rather than in the muscle during the early phase of dermatomyositis.Construction of Human Immune and Naive scFv Libraries.Infliximab for rheumatoid arthritis.
P2860
Q27022559-CC64D5FA-7DA7-4C49-8DAF-F0B41DD73292Q34560553-6774D5FF-A010-4ED6-A227-DA4F6D504A42Q34962946-9F4D9FD8-F2BC-49CD-9F1E-4CAF17F9AB31Q35551774-EF8BECEB-E6DB-45DC-A4C1-9BB7BA6DFAEFQ35553451-D256F966-FA6F-42C9-9018-0E1EB87B0CB2Q35579352-0AFAB1F1-A0F2-4BBD-9BE9-BD5D6623F495Q35579517-63CDB36A-2A79-4127-B97D-2233F84C98ECQ35638252-22D9AA52-1E5E-4C62-995A-BFE8108BCAACQ36171750-C9A12A74-9246-4C8F-9D6F-E08E2094BFB8Q36536886-4DAE152E-67DE-4D07-87AF-71FB62F171D5Q36555104-A2340FC4-0DA1-42D0-834C-4E904AEEBFD8Q41142790-98D2174B-C7CF-4271-AF82-4B31427B613EQ44852650-FE7D2F5A-54CD-40A5-B87B-E48E57AF1D85Q47148016-95BA7DBA-38FA-4C2D-845A-046647DD6608Q50108558-23C75B28-7633-4843-AD1B-6E5E277D94B4Q52856626-E5C87097-0952-4467-B5DD-809C057C7516
P2860
Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatment
description
1999 nî lūn-bûn
@nan
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Summary of clinical trials in ...... ab, an anti-TNFalpha treatment
@ast
Summary of clinical trials in ...... ab, an anti-TNFalpha treatment
@en
type
label
Summary of clinical trials in ...... ab, an anti-TNFalpha treatment
@ast
Summary of clinical trials in ...... ab, an anti-TNFalpha treatment
@en
prefLabel
Summary of clinical trials in ...... ab, an anti-TNFalpha treatment
@ast
Summary of clinical trials in ...... ab, an anti-TNFalpha treatment
@en
P2093
P2860
P356
P1476
Summary of clinical trials in ...... ab, an anti-TNFalpha treatment
@en
P2093
Harriman G
Schaible TF
P2860
P356
10.1136/ARD.58.2008.I61
P407
P478
58 Suppl 1
P577
1999-11-01T00:00:00Z